Nanovibronix (NASDAQ:NAOV – Get Free Report) and Veracyte (NASDAQ:VCYT – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.
Analyst Recommendations
This is a summary of current recommendations for Nanovibronix and Veracyte, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Veracyte | 1 | 3 | 5 | 1 | 2.60 |
Veracyte has a consensus price target of $44.38, indicating a potential downside of 7.07%. Given Veracyte’s stronger consensus rating and higher possible upside, analysts clearly believe Veracyte is more favorable than Nanovibronix.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $2.69 million | 1.66 | -$3.70 million | ($41.74) | -0.10 |
| Veracyte | $495.14 million | 7.62 | $24.14 million | $0.38 | 125.66 |
Veracyte has higher revenue and earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
16.4% of Nanovibronix shares are held by institutional investors. 5.2% of Nanovibronix shares are held by insiders. Comparatively, 1.4% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Nanovibronix has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500.
Profitability
This table compares Nanovibronix and Veracyte’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Veracyte | 6.12% | 7.23% | 6.58% |
Summary
Veracyte beats Nanovibronix on 12 of the 15 factors compared between the two stocks.
About Nanovibronix
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.
About Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
